Company Profile
D. Western Therapeutics Institute, Inc., a biotechnology company focuses on discovery and development of various drugs. It offers GLANATEC and GLA-ALPHA, an ophthalmic solution for the treatment of glaucoma/ocular hypertension.
Its portfolio also includes H-1337, a multi-kinase inhibitor that has started Phase IIb clinical trials for the treatment of glaucoma/ocular hypertension, DW-1001, an ophthalmic drug, and DW-1002, an ophthalmic surgical adjuvant for cataract surgeries, and ILM, ALC, ERM, and PVR membrane staining.
The company is also developing DW-5LBT, a lidocaine patch for neuropathic pain after shingles; and DWR-2206, a regenerative medicine cell-product for bullous keratopathy. Founded in 1999, D. Western Therapeutics Institute is headquartered in Nagoya, Japan.